Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

VIVUS, Inc. company was founded in 1991 and is headquartered in Mountain View, California. VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in Phase III clinical trials for obesity and in Phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the two of the Phase III studies are in process and one Phase III study has been completed; Qnexa for treating diabetes, for which a one-year Phase II study has been completed; Avanafil, is being developed for the treatment of erectile dysfunction; for which Phase III studies are in process, and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed.

Protide Pharmaceuticals is pro-cell. The firm focuses on developing new technologies for cellular and transfusion therapies, including gene therapies, to treat cancer and genetic disorders and to improve cell transplantation and engineering. To fund its work, Protide sells nearly 20 products under the Celox Laboratories brand to its academic, drug, and diagnostic research clients around the world. These products include serum-free growth mediums and supplements, as well as solutions used to cryopreserve cells and tissues. ICN Pharmaceuticals has a non-exclusive global marketing agreement for certain products. Protide also has a private-label manufacturing deal with a division of Sigma-Aldrich.

Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas. Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Biolex uses its LEX System and "Plantibodies" technologies for harvesting proteins from Lemna, an aquatic plant, and genetically transforming them into monoclonal antibodies for use in treating human diseases such as hepatitis C. Its lead drug candidate, Locteron, when combined with ribavarin, greatly reduces the viral load of the disease while causing fewer side effects. Its BLX-155 is used to dissolve blood clots; BLX-301 is designated for treating non-Hodgkin's B-cell lymphoma. Chairman Chris Hegal owns just under 25% of the company. Biolex has withdrawn its IPO filing.

Bilcare, Inc., formerly ProClinical Pharmaceutical Services, is in favor of pharma. Bilcare, Inc. company, which also operates as Bilcare Global Clinical Services, is the American arm of parent company Bilcare Ltd. Its aim is to help pharmaceutical companies prepare for and conduct clinical trials. Bilcare's offerings include a wide range of analytical research, formulation development, manufacturing, and packaging and labeling of clinical supplies. Logistics services include the storage, distribution, reconciliation, and destruction of clinical trial supplies and investigational medicines. Its services encompass all levels of pharmaceutical drug trials.

QuA Vodis aims to help biotechnology and pharmaceutical companies get where they are going. The company, whose name shouldn't be confused with the movie Quo Vadis, offers interim management, quality assurance system development and training, and regulatory assistance to firms engaged in human and veterinary medical research. Its main focus for consultations is to enable the organizations to maintain operations and quality with as little internal disruption as possible. QuA Vodis has experience working with products such as sterile injectibles, radiopharmaceuticals, and blood and tissue products.

Shionogi & Co. wants to kill it like a shinobi (i.e. ninja) in the night. The Japanese drug firm is a leading maker of antibiotics in its home country, with a full lineup of oral and injectable anti-infectives. It has been expanding its pipeline and its portfolio of marketed products to encompass other therapeutic areas as well, with programs in metabolic conditions and pain management. Through partnerships with large global firms, it owns Japanese market rights to some big name drugs, including AstraZeneca's blood pressure drug Crestor (which Shionogi helped develop); Purdue Pharma's pain therapy OxyContin; and Merck & Co. allergy medication Claritin.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.